Co-op – Government Affairs
About the job
- Currently enrolled as a junior or senior in an accredited undergraduate program, or currently enrolled in an accredited Master of Public Policy, Master of Public Health, or Juris Doctor program.
- An interest in government affairs, policy, advocacy, and United Therapeutics’ mission.
- An interest in health policy, life sciences, biotechnology, and the pharmaceutical industry.
- Strong research and analytical skills.
- Good written and verbal communication abilities.
- Proficiency in Microsoft Office, including PowerPoint, Word, and Excel.
- Strong analytical and problem-solving skills.
- Research upcoming legislation that could affect United Therapeutics, its patients, or its business.
- Maintain and expand United Therapeutics’ use of legislation tracking software.
- Analyze legislation and summarize its potential effects on United Therapeutics, its patients, or its business.
- Travel to United Therapeutics locations across the country to engage with lobbyists and local partners.
- Monitor and report on the evolving political and regulatory environment for life sciences and regulatory decision-making.
- Advocate for United Therapeutics in relationship-building activities with government entities.
- Detail policy agendas to help advance United Therapeutics’ advocacy goals.
- Attend meetings to gain insight from clients, local government officials, and relevant stakeholders.
- Travel to conferences and stakeholder gatherings across the country to represent the Government Affairs team in industry-specific policy settings.
- Update United Therapeutics’ reporting obligations with local, state, and federal governments.
- Support policy development in compliance with emerging regulatory requirements.
- Assist in preparing official documents, including reports, memos, and other communications for external and internal distribution.
- Majoring in Natural Sciences, Economics, Public Policy, History, Pre-Law or Political Science is preferred, although other majors are welcome to apply.
- Prior experience working in government affairs, campaigns, or a related field.
About the company
United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.
Company Size
N/A
Company Stage
IPO
Headquarters
Silver Spring, Maryland
Founded
1996
Get referred to United Therapeutics Corporation
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA accepted ralinepag NDA August 2026 and nebulized Tyvaso sNDA September 2026.
- Q2 2026 net income rose to $333 million; buybacks retired 5.84% shares.
- Phase 3 ADVANCE OUTCOMES and TETON showed improvement across PAH and IPF programs.
What critics are saying
- Q2 2026 revenue fell 2%; Tyvaso sales dropped, exposing heavy product concentration.
- Liquidia’s appeals and labeling fights can still blunt Treprostinil economics by 2027.
- If ralinepag and IPF filings disappoint FDA, United Therapeutics remains a single-portfolio biotech.
What makes United Therapeutics Corporation unique
- Martine Rothblatt built United Therapeutics around PAH drugs plus xenotransplantation, with three operating organ sites.
- September 2026 Delaware ruling strengthened its treprostinil patent moat against Liquidia’s Yutrepia.
- Stewartville’s August 12, 2026 DPF facility expands gene-edited pig organ production capacity.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Holidays
Paid Vacation
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Conference Attendance Budget
Professional Development Budget
Professional Certification Support
Tuition Reimbursement
Stock Options
Company Equity
Employee Stock Purchase Plan
Relocation Assistance
Employee Referral Bonus
Performance Bonus
Profit Sharing
Sabbatical Leave
Hybrid Work Options
Remote Work Options
Flexible Work Hours
ParentAL Leave
Company News
Varda raises $251M to leverage gravity in space for drug production. October 2, 2026 | Capitalizing on space's microgravity, the United Therapeutics-partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules. Varda Space Industries has raised $251 million to manufacture medicines in space for patients on Earth. Lux Capital and Natural Capital co-led the series D round for Varda, valuing the company at $1.6 billion, Reuters reported on Wednesday. Varda, which was set up in 2021 by former SpaceX engineer Will Bruey and Founders Fund partner Delian Asparouhov, has now raised $598 million in total since its founding. The California-based startup launched its first mission in 2023 and has completed six successful reentries. Varda has booked 28 launches with SpaceX and other providers between 2027 and 2029, Reuters reported on Wednesday. The support reflects the belief that Varda is "the first and only company delivering a real cadence of launches and reentries," Shahin Farshchi, partner at Lux Capital, said in a prepared statement. Space's lower levels of gravity, which make objects seem weightless, influence crystal formation in ways that could affect drug properties such as stability and bioavailability. Evidence of the microgravity's effect on drug molecules has fueled decades of research. NASA sponsored a report on the topic in 1978, and Merck's space station research informed its subcutaneous Keytruda formulation. With the cost of sending a kilogram to orbit falling 96% from 1960 to 2025 and forecast to drop further through 2040, one barrier to commercially viable drug production in space is lowering. Varda is among the companies seeking to capitalize on the shift. The company launches its capsules into orbit aboard commercial rockets, such as SpaceX's Falcon 9. The capsules contain equipment for processing pharmaceuticals in orbit. After completing processing, the capsule separates from the orbital satellite, returns to Earth and is recovered for analysis. Other groups have shown that a small quantity of space-grown crystals can support multiple terrestrial production batches. In May, United Therapeutics partnered with Varda to develop improved formulations of treatments for rare lung indications. The pact supports the exploration of "how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments," United Therapeutics CEO Martine Rothblatt said in a statement at the time. Varda and United Therapeutics have competition in the race to discover and make drugs in orbit. Space Microgravity Development (SpaceMD), part of the space and defense technology company Redwire, has given former Merck researcher Paul Reichert a strategic advisory role as it pursues orbital research and manufacturing. SpaceMD has signed a contract for a mission using Starfall, SpaceX's recently launched in-space manufacturing program. And Voyager Technologies operates research facilities aboard the International Space Station. The company's capacity, which supports a microgravity-enabled drug discovery pact with Space LiinTech, will be enhanced next year with a system for automated drug screening. Nick is a freelance writer who has been reporting on the global life sciences industry since 2008.
Liquidia slumps after US court rules for United Therapeutics in patent fight. By Thomson Reuters Sep 30, 2026 | 3:41 PM Sept 30 (Reuters) - Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics, dealing a major blow to the treatment's commercial outlook. The US District Court for the District of Delaware found that Liquidia's dry-powder drug, Yutrepia, infringed two foundational claims of United Therapeutics' '327 patent. The patent covers methods of treating pulmonary hypertension-associated interstitial lung disease, or PH-ILD, using inhaled treprostinil and certain dry-powder delivery features. In a related order, the court denied Liquidia's motion to throw out evidence regarding United Therapeutics' patent ownership, ruling that Liquidia had received adequate notice before trial and failed to make timely objections. "This is a key element of the case for Liquidia, and denial of the motion to strike has negative readthrough to the final decision on the case," said Raymond James analyst Ryan Deschner. The decision strengthens legal protections for United Therapeutics' blockbuster inhalation treatment, Tyvaso. Its shares jumped 12.3% to $540.54 on the ruling. Leerink Partners analysts said the court ruling gives United Therapeutics what looks like a "'win', essentially" by confirming that Yutrepia infringes a "valid UTHR patent." While, RBC Capital Markets analyst Lisa Walter said it "significantly clouds the path" for Yutrepia to compete. "We respectfully disagree with the court's decision... and are fully prepared to pursue all available appellate options," Liquidia CEO Roger Jeffs said in a statement. Liquidia, Jeffs said, plans to ask the US FDA to remove the PH-ILD indication from Yutrepia's label. Shares of Liquidia hit their lowest level in nearly four months, putting the company on track to lose about $3.18 billion from its market value, if losses hold. A final judgment is expected in about a week, analysts said. (Reporting by Christy Santhosh and Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Helicopter Museum honors hydrogen-powered flight team. WEST CHESTER, PA - The American Helicopter Museum and Education Center (AHMEC) is excited to announce that it has selected the team from United Therapeutics subsidiary Unither Bioélectronique and Robinson Helicopter Company to receive the 2026 AHMEC Achievement Award. The award recognizes the team's historic first flight of a piloted, hydrogen-powered helicopter - a significant milestone in the development of zero-emission vertical flight. The achievement involved replacing the conventional Lycoming engine in a Robinson R44 helicopter with a hydrogen fuel-cell system, a lithium-ion battery pack to provide additional power when needed, and an electric motor. According to Mikaël Cardinal, Vice President of Program Management at Unither Bioélectronique, approximately 90 percent of the energy used during the flight was supplied by the hydrogen fuel cells. Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics has been a driving force behind the development of sustainable aviation technologies and is a past recipient of the AHMEC Achievement Award for her leadership in the development of the R44 electric-powered helicopter. "Every year, we solicit nominations for the AHMEC Achievement Award, and this year it was evident that the hydrogen-powered helicopter team was the clear choice," said Dan Newman, Chairman of AHMEC's Board of Trustees. "We are proud to recognize this remarkable achievement and present the award during the museum's 30th anniversary celebration on October 18, 2026." Established in 2009, the AHMEC Achievement Award is presented annually by the Museum's Board of Trustees to an individual or organization that has made a significant contribution to the advancement of vertical flight during the preceding year. Discover more Newspapers Geographic Reference Marc Sheffler, Past Chairman of the Board of Trustees and Chair of the Achievement Award Committee, noted that Unither Bioélectronique and Robinson Helicopter Company join an impressive group of past award recipients, including the AeroVelo human-powered helicopter team, the Mars Ingenuity helicopter team, and Jeff Bezos for Amazon Prime Air. The 2026 AHMEC Achievement Award will be presented during a ceremony at the American Helicopter Museum and Education Center on October 18, 2026, as part of the museum's 30th anniversary celebration. Discover more City & Local Guides Demographics Newspapers About the American Helicopter Museum and Education Center The American Helicopter Museum and Education Center, located at 1220 American Boulevard in West Chester, Pennsylvania, is the nation's premier aviation museum devoted exclusively to rotary-wing flight. Established in 1996, the nonprofit organization collects, preserves, restores, and displays historic rotorcraft, including more than 35 civilian and military helicopters, autogyros, and convertiplanes. Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources - free for everyone. If you value that, click here to become a patron today.
Did Dolly die of her own advice? The independents. Dolly Parton put $1 million into Vanderbilt's early Moderna-related research, sang "Vaccine, vaccine, vaccine, vaccine" to the tune of Jolene, told "cowards" not to be a "chicken squat" - and died at 80 after a brief battle with cancer her team never named. This episode is not a coroner's report. It's about the advice, the playbook, and people on a ship who now say they regret the shot. Self-ownership is the relationship to yourself. Informed consent is the relationship to everyone else. COVIDmania smashed both: hide the downside, ban the question, mandate the product, zero manufacturer liability - then call it a "choice." Also on this show: the Tom Woods cruise, a note from every dinner table (regret vs blame), Fauci-world "delete this, then delete it from trash," and the old Anheuser-Busch campus in Merrimack sold to United Therapeutics, a company specializing in rare-disease work, xenotransplantation, organ printing. Not a data center. Worth eyeballs. If you own the body, you own the guess. The state does not live with the side effects. You do. carlagericke.com Chapters 0:00 Live from the Free State 0:38 Back from holiday / pledge from the porch 1:12 What's on the show 2:01 Merrimack campus sold - United Therapeutics 4:41 Did Dolly die of her own advice? 6:06 Why Dolly still mattered 7:35 Tom Woods cruise 10:43 Regret on the boat 13:25 Vaccines as the frame for self-ownership 16:05 My body, my choice - until it wasn't 17:32 Self-ownership vs informed consent 19:13 The celebrity playbook 20:13 Experimental + no liability = not consent 21:28 What happens when the experts are wrong 23:33 Three conditions for real consent 26:31 Should this go in my body? 27:38 Latency, the kicked can, closing #DollyParton #InformedConsent #SelfOwnership #Covid #NewHampshire #FreeState #TomWoods #Independence #CarlaGericke #Covidmania BONUS! What is xenotransplantation? Xenotransplantation is putting an organ or tissue from one species into another. In the news it almost always means pig | human. Not sci-fi printing from scratch. A pig is bred (usually gene-edited so the human immune system is less likely to attack the organ), the kidney or heart is taken out, and surgeons sew it into a person who would otherwise die waiting for a human donor. Why they want it Human organs are scarce. Thousands die on waitlists. A pig organ is a proposed spare. Why it sounds "sus" * Animal viruses riding along (PERVs - pig viruses) * Immune rejection, even with edits * First patients have been last-ditch cases; some lived weeks or months, not a settled spare-parts aisle * Ethics: breeding animals as organ farms * "Organ printing" is a different pitch (cells + scaffold in a lab). Companies sometimes sell both stories on one campus. United Therapeutics angle They work on lungs/pulmonary disease and have been in the pig-organ / bioengineered-organ lane. Buying a big campus does not mean Merrimack is growing chimeric zombies. It means a firm that wants to industrialize replacement parts now has square footage. One-line for air Xeno = animal organ in a human. The bet is pigs. The risk is viruses, rejection, and a factory logic for bodies. Worth watching. Not the same sentence as "they printed a person."
Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M. * DAVID LANE/UNION LEADER The Anheuser-Busch Merrimack Brewery site (shown here on Wednesday) was sold to United Therapeutics Corporation.